LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

Search

PerkinElmer Inc

Fechado

SetorSaúde

0

Visão Geral

Variação de preço das ações

24h

Atual

Mín

Máximo

Indicadores-chave

By Trading Economics

Rendimento

-8.6M

47M

Vendas

-21M

699M

P/E

Médio do Setor

54.418

79.874

EPS

0.4

Rendimento de Dividendos

0.28

Margem de lucro

6.675

Funcionários

11,000

EBITDA

-14M

181M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+6.15% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.28%

2.31%

Próxima data de ex-dividendo

16 de jan. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

976M

12B

Abertura anterior

0

Fecho anterior

0

Sentimento de Notícias

By Acuity

24%

76%

56 / 374 Ranking em Healthcare

PerkinElmer Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de nov. de 2025, 16:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27 de nov. de 2025, 15:32 UTC

Aquisições, Fusões, Aquisições de Empresas

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27 de nov. de 2025, 23:50 UTC

Conversa de Mercado

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27 de nov. de 2025, 23:50 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de nov. de 2025, 16:05 UTC

Conversa de Mercado

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27 de nov. de 2025, 16:04 UTC

Conversa de Mercado

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27 de nov. de 2025, 15:54 UTC

Aquisições, Fusões, Aquisições de Empresas

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27 de nov. de 2025, 15:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27 de nov. de 2025, 15:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27 de nov. de 2025, 15:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27 de nov. de 2025, 15:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27 de nov. de 2025, 15:11 UTC

Conversa de Mercado

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27 de nov. de 2025, 14:26 UTC

Conversa de Mercado

Hermes' Outperformance Gap Could Narrow -- Market Talk

27 de nov. de 2025, 14:11 UTC

Conversa de Mercado

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27 de nov. de 2025, 14:11 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

27 de nov. de 2025, 13:35 UTC

Conversa de Mercado

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27 de nov. de 2025, 13:33 UTC

Conversa de Mercado

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27 de nov. de 2025, 13:22 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

27 de nov. de 2025, 13:22 UTC

Conversa de Mercado

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27 de nov. de 2025, 13:17 UTC

Conversa de Mercado

LVMH Should Be Able to Recover Next Year -- Market Talk

27 de nov. de 2025, 11:13 UTC

Conversa de Mercado

European Gas Prices Come Under Pressure -- Market Talk

27 de nov. de 2025, 11:07 UTC

Ganhos

Genting: Positive About Prospects Over Longer Term

27 de nov. de 2025, 11:06 UTC

Ganhos

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27 de nov. de 2025, 11:04 UTC

Ganhos

Genting: International Travel Demand Expected to Remain Resilient

27 de nov. de 2025, 11:04 UTC

Ganhos

Genting: Global Growth Expected to Remain Subdued

27 de nov. de 2025, 11:04 UTC

Ganhos

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27 de nov. de 2025, 10:59 UTC

Ganhos

Genting Bhd 3Q Net Profit Fell 86% on Year

27 de nov. de 2025, 10:58 UTC

Ganhos

Genting Bhd 3Q Rev Rose 14% on Year

27 de nov. de 2025, 10:56 UTC

Ganhos

Genting Bhd 3Q Net MYR30.3M

27 de nov. de 2025, 10:56 UTC

Ganhos

Genting Bhd 3Q EPS MYR0.0079

Comparação entre Pares

Variação de preço

PerkinElmer Inc Previsão

Preço-alvo

By TipRanks

6.15% parte superior

Previsão para 12 meses

Média 111.1 USD  6.15%

Máximo 125 USD

Mínimo 100 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para PerkinElmer Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

8

Comprar

3

Manter

0

Vender

Sentimento

By Acuity

56 / 374 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat